$BLCO
Bausch + Lomb Corp Stock $blco

$blco Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000186074223000015 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.035B	$931.0M	$889.0M
YoY Change	9.99%	4.72%	0.91%
Cost Of Revenue	$417.0M	$372.0M	$348.0M
YoY Change	10.03%	6.9%
Gross Profit	$618.0M	$559.0M	$541.0M
YoY Change	9.96%	3.33%
Gross Profit Margin	59.71%	60.04%	60.85%
Selling, General & Admin	$399.0M	$418.0M	$343.0M
YoY Change	8.42%	21.87%	7.86%
% of Gross Profit	64.56%	74.78%	63.4%
Research & Development	$85.00M	$77.00M	$77.00M
YoY Change	13.33%	0.0%	14.93%
% of Gross Profit	13.75%	13.77%	14.23%
Depreciation & Amortization	$56.00M	$91.00M	$95.00M
YoY Change	-42.86%	-4.21%
% of Gross Profit	9.06%	16.28%	17.56%
Operating Expenses	$540.0M	$495.0M	$420.0M
YoY Change	21.9%	17.86%	9.09%
Operating Profit	$78.00M	-$2.000M	$54.00M
YoY Change	39.29%	-103.7%	-36.47%
Interest Expense	-$62.00M	-$53.00M	-$25.00M
YoY Change	113.79%	112.0%
% of Operating Profit	-79.49%		-46.3%
Other Income/Expense, Net	-$17.00M	-$9.000M	-$2.000M
YoY Change	-1800.0%	350.0%	0.0%
Pretax Income	-$19.00M	-$55.00M	$29.00M
YoY Change	-170.37%	-289.66%	-62.34%
Income Tax	$10.00M	$33.00M	$6.000M
% Of Pretax Income			20.69%
Net Earnings	-$32.00M	-$90.00M	$20.00M
YoY Change	-740.0%	-550.0%	-25.93%
Net Earnings / Revenue	-3.09%	-9.67%	2.25%
Basic Earnings Per Share	-$0.09	-$0.26	$0.06
Diluted Earnings Per Share	-$0.09	-$0.26	$0.06
COMMON SHARES
Basic Shares Outstanding	350.3M shares	350.0M shares	350.0M shares
Diluted Shares Outstanding	350.5M shares	350.0M shares	350.0M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$384.0M	$346.0M	$190.0M
YoY Change	-12.13%	82.11%
Cash & Equivalents	$384.0M	$346.0M	$190.0M
Short-Term Investments
Other Short-Term Assets	$441.0M	$427.0M	$194.0M
YoY Change	55.28%	120.1%
Inventory	$699.0M	$697.0M	$598.0M
Prepaid Expenses
Receivables	$791.0M	$714.0M	$737.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.315B	$2.184B	$1.719B
YoY Change	15.69%	27.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.294B	$1.296B	$1.225B
YoY Change	4.1%	5.8%
Goodwill	$4.540B	$4.522B	$4.553B
YoY Change	1.05%	-0.68%
Intangibles	$2.021B	$2.031B	$2.196B
YoY Change	-5.16%	-7.51%
Long-Term Investments
YoY Change
Other Assets	$207.0M	$213.0M	$188.0M
YoY Change	-6.76%	13.3%
Total Long-Term Assets	$9.000B	$8.985B	$9.188B
YoY Change	-0.01%	-2.21%
TOTAL ASSETS
Total Short-Term Assets	$2.315B	$2.184B	$1.719B
Total Long-Term Assets	$9.000B	$8.985B	$9.188B
Total Assets	$11.32B	$11.17B	$10.91B
YoY Change	2.84%	2.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$348.0M	$389.0M	$251.0M
YoY Change	-2.52%	54.98%
Accrued Expenses	$952.0M	$840.0M	$841.0M
YoY Change	6.85%	-0.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$25.00M	$25.00M
YoY Change	0.0%
Total Short-Term Liabilities	$1.325B	$1.254B	$1.092B
YoY Change	4.08%	14.84%
LONG-TERM LIABILITIES
Long-Term Debt	$2.604B	$2.508B	$2.220B
YoY Change	7.74%	12.97%
Other Long-Term Liabilities	$342.0M	$341.0M	$276.0M
YoY Change	3.32%	23.55%
Total Long-Term Liabilities	$2.946B	$2.849B	$276.0M
YoY Change	7.21%	932.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.325B	$1.254B	$1.092B
Total Long-Term Liabilities	$2.946B	$2.849B	$276.0M
Total Liabilities	$4.285B	$4.117B	$3.691B
YoY Change	6.3%	11.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.0M	-$84.00M	$20.00M
YoY Change	-564.0%	-520.0%
Common Stock	$8.321B	$8.305B	$8.219B
YoY Change	2.88%	1.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.958B	$6.983B	$7.140B
YoY Change
Total Liabilities & Shareholders Equity	$11.32B	$11.17B	$10.91B
YoY Change	2.84%	2.4%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$32.00M	-$90.00M	$20.00M
YoY Change	-740.0%	-550.0%	-25.93%
Depreciation, Depletion And Amortization	$56.00M	$91.00M	$95.00M
YoY Change	-42.86%	-4.21%
Cash From Operating Activities	-$24.00M	-$56.00M	$3.000M
YoY Change	-115.38%	-1966.67%	-98.4%
INVESTING ACTIVITIES
Capital Expenditures	$27.00M	$37.00M	$42.00M
YoY Change	-179.41%	-11.9%	-6.67%
Acquisitions
YoY Change
Other Investing Activities	-$1.000M	-$27.00M	$1.000M
YoY Change	0.0%	-2800.0%
Cash From Investing Activities	-$28.00M	-$64.00M	-$41.00M
YoY Change	-20.0%	56.1%	-14.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$6.000M	$0.00
YoY Change
Cash From Financing Activities	90.00M	$91.00M	$52.00M
YoY Change	-37.93%	75.0%	-145.61%
NET CHANGE
Cash From Operating Activities	-24.00M	-$56.00M	$3.000M
Cash From Investing Activities	-28.00M	-$64.00M	-$41.00M
Cash From Financing Activities	90.00M	$91.00M	$52.00M
Net Change In Cash	38.00M	-$22.00M	$13.00M
YoY Change	-85.71%	-269.23%	-31.58%
FREE CASH FLOW
Cash From Operating Activities	-$24.00M	-$56.00M	$3.000M
Capital Expenditures	$27.00M	$37.00M	$42.00M
Free Cash Flow	-$51.00M	-$93.00M	-$39.00M
YoY Change	-126.84%	138.46%	-127.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001860742
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Bausch & Lomb Corp
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41380
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1613662
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Applewood Crescent
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Vaughan
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	ON
CY2023Q1	dei	Entity Address Country EntityAddressCountry	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	L4K 4B4
CY2023Q1	dei	City Area Code CityAreaCode	905
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	695-7700
CY2023Q1	dei	Security12b Title Security12bTitle	Common Shares, No Par Value
CY2023Q1	dei	Trading Symbol TradingSymbol	BLCO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	350258115	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354000000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	12000000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	26000000	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	714000000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	724000000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	697000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	628000000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	415000000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	370000000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	405000000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2184000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2137000000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1296000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1300000000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2031000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2058000000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	4522000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	4507000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	923000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	927000000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	213000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	215000000	usd
CY2023Q1	us-gaap	Assets Assets	11169000000	usd
CY2022Q4	us-gaap	Assets Assets	11144000000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	389000000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	840000000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	901000000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	25000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	25000000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1254000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1296000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7000000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	341000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	329000000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2508000000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2411000000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4117000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4043000000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	350169790	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	350169790	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	350169790	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	350169790	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	8305000000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	8285000000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6000000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1238000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1258000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6983000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7033000000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	69000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	68000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7052000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7101000000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11169000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11144000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	931000000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	889000000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	418000000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	343000000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	77000000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	77000000	usd
CY2023Q1	blco	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	57000000	usd
CY2022Q1	blco	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	65000000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-9000000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	933000000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	835000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2000000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	54000000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	50000000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	20000000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6000000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55000000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	29000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33000000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-88000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	23000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2000000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-90000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	20000000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	350000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	350000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	350000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	350000000	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-88000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	23000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	21000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	2000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	4000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	19000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-64000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-69000000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-41000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1000000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	3000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70000000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7101000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24000000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-88000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	19000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7052000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9402000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2022Q1	blco	Net Parent Investment Decrease In Conjunction With Legal Reorganization NetParentInvestmentDecreaseInConjunctionWithLegalReorganization	2200000000	usd
CY2022Q1	blco	Adjustments To Additional Paid In Capital Distributions To Affiliates AdjustmentsToAdditionalPaidInCapitalDistributionsToAffiliates	55000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	23000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-64000000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7216000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-88000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	23000000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	91000000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	95000000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3000000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023Q1	blco	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	5000000	usd
CY2022Q1	blco	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	7000000	usd
CY2023Q1	blco	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	6000000	usd
CY2022Q1	blco	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-43000000	usd
CY2023Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	0	usd
CY2022Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	2000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24000000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16000000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-5000000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1000000	usd
CY2023Q1	blco	Derivative Gain Excluded Component DerivativeGainExcludedComponent	3000000	usd
CY2022Q1	blco	Derivative Gain Excluded Component DerivativeGainExcludedComponent	0	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4000000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	9000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	68000000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	41000000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19000000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3000000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	31000000	usd
CY2022Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8000000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6000000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6000000	usd
CY2023Q1	us-gaap	Proceeds From Derivative Instrument Investing Activities ProceedsFromDerivativeInstrumentInvestingActivities	6000000	usd
CY2022Q1	us-gaap	Proceeds From Derivative Instrument Investing Activities ProceedsFromDerivativeInstrumentInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	100000000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	blco	Net Borrowings Financing Activities NetBorrowingsFinancingActivities	0	usd
CY2022Q1	blco	Net Borrowings Financing Activities NetBorrowingsFinancingActivities	31000000	usd
CY2023Q1	blco	Net Transfers Financing Activities NetTransfersFinancingActivities	0	usd
CY2022Q1	blco	Net Transfers Financing Activities NetTransfersFinancingActivities	-21000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	91000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52000000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7000000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22000000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	380000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	358000000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190000000	usd
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	0	usd
CY2022Q1	us-gaap	Notes Issued1 NotesIssued1	2200000000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. The Company operates in three reportable segments: (i) Vision Care segment which includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter (“OTC”) eye drops and eye vitamins, (ii) Ophthalmic Pharmaceuticals segment which consists of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases and (iii) Surgical segment which consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes intraocular lenses (“IOLs”) and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. See Note 18, “SEGMENT INFORMATION” for additional information regarding these reportable segments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC holding, directly or indirectly, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.6%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common shares of Bausch + Lomb as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 28, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Separation of Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, BHC announced its plan to separate Bausch + Lomb into an independent, publicly traded company, separate from the remainder of BHC (the “Separation”), commencing with an initial public offering of Bausch + Lomb's common shares (as further described below). Prior to January 1, 2022, Bausch + Lomb had nominal assets and liabilities. In connection with the B+L IPO (as defined below), BHC transferred to Bausch + Lomb, in a series of steps, all the entities, assets, liabilities and obligations that Bausch + Lomb held upon completion of the B+L IPO pursuant to a Master Separation Agreement (the “MSA”) with BHC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement related to the initial public offering (the “IPO”) of Bausch + Lomb’s common shares (the “B+L IPO”) was declared effective on May 5, 2022, and Bausch + Lomb’s common shares began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol “BLCO”, on May 6, 2022. Bausch + Lomb also obtained a final receipt to its final Canadian base PREP prospectus on May 5, 2022. Prior to the B+L IPO, Bausch + Lomb was a wholly-owned subsidiary of BHC. On May 10, 2022, a wholly-owned subsidiary of BHC (the “Selling Shareholder”) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share (less the applicable underwriting discount), pursuant to the Bausch + Lomb prospectuses. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters for the B+L IPO partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less the applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired. The Selling Shareholder received all net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters. As of April 28, 2023, BHC directly or indirectly held 310,449,643 common shares of Bausch + Lomb, which represented approximately 88.6% of the common shares of Bausch + Lomb. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the full Separation of Bausch + Lomb, which includes the transfer of all or a portion of BHC’s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the “Distribution”), is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals and other factors and is subject to various risk factors relating to the Separation. See Item 1A. “Risk Factors” in the Company’s Annual Report Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (“CSA”) on February 22, 2023 (the “Annual Report”) for additional information on the risks associated with the Separation. Bausch + Lomb understands that BHC continues to believe that completing the B+L Separation makes strategic sense and that BHC continues to evaluate all factors and considerations related to completing the Separation, including the effect of the lawsuit filed against Norwich Pharmaceuticals Inc. in connection with its Abbreviated New Drug Application ("ANDA") for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaxamin) 550 mg tablets (including BHC’s ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in such lawsuit).</span></div>
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company’s Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that certain global macroeconomic conditions, including, but not limited to, those related to the COVID-19 pandemic and other macroeconomic factors, including those related to inflation and supply chain, will have on the Company's operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of finite-lived intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants, reporting unit fair values for testing goodwill for impairment; acquisition-related contingent consideration liabilities; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; the fair value of cross-currency swaps; and the fair value of foreign currency exchange contracts. Prior to the B+L IPO, significant estimates made by management also included the related allocations described in the basis of presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All allocations and estimates in these Condensed Consolidated Financial Statements are based on assumptions that management believes are reasonable. On an ongoing basis, management reviews its allocations and estimates to ensure that these allocations and estimates appropriately reflect changes in the Company's business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company's business, financial condition, cash flows and results of operations could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which certain global macroeconomic conditions, including, but not limited to, those related to the COVID-19 pandemic and its overall impact on inflation and supply chain, may continue to impact the Company’s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company’s control. The Company has assessed the possible effects and outcomes of these macroeconomic conditions on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable.</span></div>
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	484000000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	351000000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	374000000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	461000000	usd
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	468000000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	320000000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	286000000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	502000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	22000000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	16000000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1000000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	1000000	usd
CY2023Q1	blco	Accounts Receivable Allowance For Foreign Exchange And Other AccountsReceivableAllowanceForForeignExchangeAndOther	-1000000	usd
CY2022Q1	blco	Accounts Receivable Allowance For Foreign Exchange And Other AccountsReceivableAllowanceForForeignExchangeAndOther	-1000000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	21000000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	16000000	usd
CY2023Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
CY2022Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	76000000	usd
CY2023Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	42000000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	53000000	usd
CY2023Q1	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	95000000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	102000000	usd
CY2022Q4	blco	Related Party Net Borrowings RelatedPartyNetBorrowings	0	usd
CY2023Q1	blco	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	0	usd
CY2022Q1	blco	Related Party Cash Pooling And General Financing Activities RelatedPartyCashPoolingAndGeneralFinancingActivities	-87000000	usd
CY2023Q1	blco	Related Party Corporate Allocations RelatedPartyCorporateAllocations	0	usd
CY2022Q1	blco	Related Party Corporate Allocations RelatedPartyCorporateAllocations	76000000	usd
CY2023Q1	blco	Related Party Benefit From Income Taxes RelatedPartyBenefitFromIncomeTaxes	0	usd
CY2022Q1	blco	Related Party Benefit From Income Taxes RelatedPartyBenefitFromIncomeTaxes	66000000	usd
CY2023Q1	blco	Related Party Total Net Transfers RelatedPartyTotalNetTransfers	0	usd
CY2022Q1	blco	Related Party Total Net Transfers RelatedPartyTotalNetTransfers	55000000	usd
CY2023Q1	blco	Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense	0	usd
CY2022Q1	blco	Related Party Net Transfers Allocated Share Based Payment Arrangement Noncash Expense RelatedPartyNetTransfersAllocatedShareBasedPaymentArrangementNoncashExpense	16000000	usd
CY2023Q1	blco	Related Party Net Transfers Other RelatedPartyNetTransfersOther	0	usd
CY2022Q1	blco	Related Party Net Transfers Other RelatedPartyNetTransfersOther	18000000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4000000	usd
CY2023Q1	blco	Net Transfers Financing Activities NetTransfersFinancingActivities	0	usd
CY2022Q1	blco	Net Transfers Financing Activities NetTransfersFinancingActivities	-21000000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5000000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4000000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9000000	usd
CY2022Q1	blco	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Acquisition-related contingent consideration adjustments
CY2023Q1	blco	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Acquisition-related contingent consideration adjustments
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	5000000	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9000000	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9000000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9000000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	180000000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	163000000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	55000000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	44000000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	462000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	421000000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	697000000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	628000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3756000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3423000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	333000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3720000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3360000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	360000000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5454000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3423000000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2031000000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5418000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3360000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2058000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	130000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	92000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	47000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	26000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	333000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	4586000000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	5000000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	84000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	4507000000	usd
CY2023Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2000000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-13000000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	4522000000	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	171000000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	196000000	usd
CY2023Q1	blco	Accrued Product Rebates Current AccruedProductRebatesCurrent	140000000	usd
CY2022Q4	blco	Accrued Product Rebates Current AccruedProductRebatesCurrent	153000000	usd
CY2023Q1	blco	Accrued Discounts And Allowances Current AccruedDiscountsAndAllowancesCurrent	78000000	usd
CY2022Q4	blco	Accrued Discounts And Allowances Current AccruedDiscountsAndAllowancesCurrent	85000000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	67000000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	66000000	usd
CY2023Q1	blco	Accrued Product Returns Current AccruedProductReturnsCurrent	62000000	usd
CY2022Q4	blco	Accrued Product Returns Current AccruedProductReturnsCurrent	59000000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	322000000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	342000000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	840000000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	901000000	usd
CY2023Q1	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0840
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0784
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24000000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24000000	usd
CY2023Q1	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	63000000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10000000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2679000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.27
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.52
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	118000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M26D
CY2023Q1	blco	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	72000000	usd
CY2022Q1	blco	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	72000000	usd
CY2023Q1	blco	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	5000000	usd
CY2022Q1	blco	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	5000000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	77000000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	77000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9000000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	8000000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	2000000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1000000	usd
CY2022Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33000000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	120000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54000000	usd
CY2023Q1	blco	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	70000000	usd
CY2022Q4	blco	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	70000000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10000000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	350000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	350000000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-90000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	20000000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	350000000.0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	350000000.0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	350000000.0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	350000000.0	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2000000	usd
CY2023Q1	blco	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	57000000	usd
CY2022Q1	blco	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	65000000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-9000000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2000000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	54000000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	50000000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	20000000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6000000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55000000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	29000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	931000000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	889000000	usd
CY2023Q1	blco	Concentration Risk Number Of Products Franchises ConcentrationRiskNumberOfProductsFranchises	10	product
CY2022Q1	blco	Concentration Risk Number Of Products Franchises ConcentrationRiskNumberOfProductsFranchises	10	product
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	931000000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	889000000	usd

Files In Submission

Name	View Source	Status
0001860742-23-000015-index-headers.html	Edgar Link	pending
0001860742-23-000015-index.html	Edgar Link	pending
0001860742-23-000015.txt	Edgar Link	pending
0001860742-23-000015-xbrl.zip	Edgar Link	pending
blco-20230331.htm	Edgar Link	pending
blco-20230331.xsd	Edgar Link	pending
exhibit1010-newhireawardxs.htm	Edgar Link	pending
exhibit102-employmentagree.htm	Edgar Link	pending
exhibit103-bl2022omnibusin.htm	Edgar Link	pending
exhibit104-2023psuagreemen.htm	Edgar Link	pending
exhibit105-2023psuagreemen.htm	Edgar Link	pending
exhibit106-2023rsuagreement.htm	Edgar Link	pending
exhibit107-2023stockoption.htm	Edgar Link	pending
exhibit108-newhireawardxps.htm	Edgar Link	pending
exhibit109-newhireawardxrs.htm	Edgar Link	pending
exhibit311q12023.htm	Edgar Link	pending
exhibit312q12023.htm	Edgar Link	pending
exhibit321q12023.htm	Edgar Link	pending
exhibit322q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
blco-20230331_cal.xml	Edgar Link	unprocessable
blco-20230331_def.xml	Edgar Link	unprocessable
blco-20230331_lab.xml	Edgar Link	unprocessable
blco-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
blco-20230331_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLCO
Bausch + Lomb Corp Stock $blco

2023 Q2 Form 10-Q Financial Statement

#000186074223000015 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLCO Bausch + Lomb Corp Stock $blco

2023 Q2 Form 10-Q Financial Statement

#000186074223000015 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLCO
Bausch + Lomb Corp Stock $blco